RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
31 Janvier 2024 - 2:00PM
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage,
immunology-based therapeutics company focused on discovering,
developing and commercializing oral small molecule therapies for
patients with significant unmet needs in inflammatory diseases and
oncology, today announced that Brian Wong, M.D., Ph.D., President
and Chief Executive Officer, will participate in a fireside chat at
the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
on Wednesday, February 7, 2024 at 2:00 p.m. ET .
To access the live webcast or subsequent
archived recording of the discussion, please visit the RAPT
Therapeutics website at
https://investors.rapt.com/events-and-presentations.
About RAPT Therapeutics,
Inc.RAPT Therapeutics is a clinical-stage,
immunology-based therapeutics company focused on discovering,
developing and commercializing oral small molecule therapies for
patients with significant unmet needs in inflammatory diseases and
oncology. Utilizing its proprietary discovery and development
engine, the Company is developing highly selective small molecules
designed to modulate the critical immune drivers underlying these
diseases. RAPT has discovered and advanced two unique drug
candidates, zelnecirnon (RPT193) and tivumecirnon (FLX475), each
targeting C-C motif chemokine receptor 4 (CCR4), for the treatment
of inflammation and cancer, respectively. The Company is also
pursuing a range of targets that are in the discovery stage of
development.
Investor Contact:Sylvia
Wheelerswheeler@wheelhouselsa.com
Media Contact:Aljanae
Reynoldsareynolds@wheelhouselsa.com
RAPT Therapeutics (NASDAQ:RAPT)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
RAPT Therapeutics (NASDAQ:RAPT)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024